vs

Side-by-side financial comparison of HANCOCK WHITNEY CORP (HWC) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

HANCOCK WHITNEY CORP is the larger business by last-quarter revenue ($295.0M vs $151.7M, roughly 1.9× Tarsus Pharmaceuticals, Inc.). HANCOCK WHITNEY CORP runs the higher net margin — 16.1% vs -5.5%, a 21.6% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -19.7%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -9.4%).

Hancock Whitney Corp. is an American bank holding company headquartered in Gulfport, Mississippi. It operates 237 branches in Mississippi, Alabama, Florida, Louisiana, and Texas. The bank is the official bank of the New Orleans Saints and issues the official debit card. The bank is also the official bank of LSU Athletics and the Louisiana Ragin' Cajuns, being the exclusive provider of credit cards for the LSU Tigers, as well as debit cards for both athletic brands.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

HWC vs TARS — Head-to-Head

Bigger by revenue
HWC
HWC
1.9× larger
HWC
$295.0M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+148.1% gap
TARS
128.4%
-19.7%
HWC
Higher net margin
HWC
HWC
21.6% more per $
HWC
16.1%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-9.4%
HWC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
HWC
HWC
TARS
TARS
Revenue
$295.0M
$151.7M
Net Profit
$47.4M
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
16.1%
-5.5%
Revenue YoY
-19.7%
128.4%
Net Profit YoY
-60.3%
63.8%
EPS (diluted)
$0.57
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HWC
HWC
TARS
TARS
Q1 26
$295.0M
Q4 25
$389.3M
$151.7M
Q3 25
$385.7M
$118.7M
Q2 25
$375.5M
$102.7M
Q1 25
$364.7M
$78.3M
Q4 24
$364.8M
$66.4M
Q3 24
$367.7M
$48.1M
Q2 24
$359.6M
$40.8M
Net Profit
HWC
HWC
TARS
TARS
Q1 26
$47.4M
Q4 25
$-8.4M
Q3 25
$127.5M
$-12.6M
Q2 25
$-20.3M
Q1 25
$-25.1M
Q4 24
$-23.1M
Q3 24
$115.6M
$-23.4M
Q2 24
$-33.3M
Operating Margin
HWC
HWC
TARS
TARS
Q1 26
Q4 25
40.7%
-5.3%
Q3 25
41.6%
-12.2%
Q2 25
38.5%
-21.6%
Q1 25
40.9%
-33.5%
Q4 24
41.3%
-36.8%
Q3 24
39.5%
-52.3%
Q2 24
40.3%
-81.6%
Net Margin
HWC
HWC
TARS
TARS
Q1 26
16.1%
Q4 25
-5.5%
Q3 25
33.0%
-10.6%
Q2 25
-19.8%
Q1 25
-32.1%
Q4 24
-34.8%
Q3 24
31.4%
-48.7%
Q2 24
-81.6%
EPS (diluted)
HWC
HWC
TARS
TARS
Q1 26
$0.57
Q4 25
$1.48
$-0.17
Q3 25
$1.49
$-0.30
Q2 25
$1.32
$-0.48
Q1 25
$1.38
$-0.64
Q4 24
$1.40
$-0.57
Q3 24
$1.33
$-0.61
Q2 24
$1.31
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HWC
HWC
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$223.7M
$417.3M
Total DebtLower is stronger
$1.6B
$72.4M
Stockholders' EquityBook value
$343.4M
Total Assets
$35.5B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HWC
HWC
TARS
TARS
Q1 26
$223.7M
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Total Debt
HWC
HWC
TARS
TARS
Q1 26
$1.6B
Q4 25
$199.4M
$72.4M
Q3 25
$210.7M
$72.3M
Q2 25
$210.6M
$72.1M
Q1 25
$210.6M
$72.0M
Q4 24
$210.5M
$71.8M
Q3 24
$236.4M
$71.7M
Q2 24
$236.4M
$71.6M
Stockholders' Equity
HWC
HWC
TARS
TARS
Q1 26
Q4 25
$4.5B
$343.4M
Q3 25
$4.5B
$335.1M
Q2 25
$4.4B
$332.6M
Q1 25
$4.3B
$342.5M
Q4 24
$4.1B
$224.5M
Q3 24
$4.2B
$237.5M
Q2 24
$3.9B
$252.2M
Total Assets
HWC
HWC
TARS
TARS
Q1 26
$35.5B
Q4 25
$35.5B
$562.2M
Q3 25
$35.8B
$534.6M
Q2 25
$35.2B
$495.0M
Q1 25
$34.8B
$500.8M
Q4 24
$35.1B
$377.0M
Q3 24
$35.2B
$376.3M
Q2 24
$35.4B
$376.8M
Debt / Equity
HWC
HWC
TARS
TARS
Q1 26
Q4 25
0.04×
0.21×
Q3 25
0.05×
0.22×
Q2 25
0.05×
0.22×
Q1 25
0.05×
0.21×
Q4 24
0.05×
0.32×
Q3 24
0.06×
0.30×
Q2 24
0.06×
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HWC
HWC
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HWC
HWC
TARS
TARS
Q1 26
Q4 25
$541.8M
$19.3M
Q3 25
$158.8M
$18.3M
Q2 25
$125.8M
$-29.4M
Q1 25
$104.2M
$-20.7M
Q4 24
$625.7M
$-22.2M
Q3 24
$162.5M
$-8.7M
Q2 24
$105.0M
$-14.4M
Free Cash Flow
HWC
HWC
TARS
TARS
Q1 26
Q4 25
$523.1M
$13.0M
Q3 25
$155.0M
$16.3M
Q2 25
$122.0M
$-30.4M
Q1 25
$100.2M
$-21.2M
Q4 24
$615.5M
$-22.3M
Q3 24
$158.6M
$-8.9M
Q2 24
$103.7M
$-15.4M
FCF Margin
HWC
HWC
TARS
TARS
Q1 26
Q4 25
134.4%
8.6%
Q3 25
40.2%
13.8%
Q2 25
32.5%
-29.6%
Q1 25
27.5%
-27.1%
Q4 24
168.7%
-33.5%
Q3 24
43.1%
-18.6%
Q2 24
28.8%
-37.8%
Capex Intensity
HWC
HWC
TARS
TARS
Q1 26
Q4 25
4.8%
4.2%
Q3 25
1.0%
1.6%
Q2 25
1.0%
1.0%
Q1 25
1.1%
0.8%
Q4 24
2.8%
0.1%
Q3 24
1.1%
0.6%
Q2 24
0.4%
2.5%
Cash Conversion
HWC
HWC
TARS
TARS
Q1 26
Q4 25
Q3 25
1.25×
Q2 25
Q1 25
Q4 24
Q3 24
1.41×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons